News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AusAm Biotechnologies Accumin Urine Albumin Test To Indicate Risk Of Complications From Heart And Kidney Disease To Be Available To Hospitals Nationwide Through Quest Diagnostics Inc. (DGX)


10/19/2005 5:12:31 PM

NEW YORK--(BUSINESS WIRE)--Dec. 21, 2004--AusAm Biotechnologies, Inc. announced today that its Accumin(TM) test for detection of the protein albumin in urine will be offered by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services. The presence of relatively high levels of albumin in the urine, a condition known as microalbuminuria, is an indicator of elevated risk for developing cardiovascular disease complications and kidney disease. The test will be available to hospital-based physicians nationwide in the first quarter of 2005 through Quest Diagnostics. Terms of the transaction were not disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES